Bone marrow transplant (BMT) recipients are prone to bacterial, viral and fungal infections. Mycobacterium tuberculosis infection can occur in these patients, but the incidence is lower than that of other infections. This report describes four patients with Mycobacterium tuberculosis infection identified from 641 adult patients who received a BMT over a 12-year period (prevalence 0.6%). The pre-transplant diagnosis was AML in two patients and CML in the other two. Pre-transplant conditioning consisted of BU/CY in three patients and CY/TBI in one. Graft-versus-host disease (GVHD) prophylaxis was MTX/CsA in three patients and T cell depletion of the graft in one patient. Sites of infection were lung (two), spine (one) and central nervous system (one). Onset of infection ranged from 120 days to 20 months post BMT. Two patients had co-existing CMV infection. One patient had graft failure. The two patients who received anti-tuberculous (TB) therapy recovered from the infection. Although the incidence of tuberculosis in BMT patients is not as high as in patients with solid organ transplants, late diagnosis due to the slow growth of the bacterium can lead to delay in instituting anti-TB therapy. A high index of suspicion should be maintained, particularly in endemic areas.
Allogeneic BMT patients have severely impaired cellmediated immunity as a result of their underlying illness, pre-transplant conditioning chemotherapy, and radiation. Those who develop acute or chronic GVHD and who subsequently receive additional immunosuppressive therapy, as well as those who receive T cell-depleted grafts, tend to have protracted impairment of their immunocompetence, particularly T cell-mediated function. 1 A high incidence of Mycobacterium tuberculosis is expected in these patients. At King Faisal Specialist Hospital and Research Centre, we analyzed our BMT database to identify allogeneic patients with Mycobacterium tuberculosis infection as confirmed by culture. Four such cases were identified. The clinical features, diagnostic approach and management are outlined in this report, and similar cases reported in the literature are reviewed.
Materials and methods
Between January 1986 and December 1997, a total of 641 allogeneic BMT procedures were carried out at King Faisal Specialist Hospital and Research Centre. Analysis of our database, which contains prospectively collected clinical information about individual cases, was carried out to identify patients with mycobacterial infections. Subsequently, the complete medical records of identified cases were carefully reviewed regarding each patients' demographics, underlying diagnosis and initial treatment, pre-transplantation history, physical examination, work-up and chest Xray, type of BMT, conditioning chemotherapy, GVHD prophylaxis, whether any graft processing was carried out, development of GVHD and its treatment, other post-BMT co-morbid conditions, site of mycobacterial infection, mycobacterial species, and procedures used to establish the diagnosis, management, and outcome. All patients transplanted were required to be HIV negative as part of pre-BMT eligibility criteria.
Case No. 1
A 40-year-old female was diagnosed and treated for AML M4-FAB sub-type in Bangladesh in 1986. She initially presented with symptoms of generalized weakness and fatigue. WBC was 30.3 × 10 9 /l. Bone marrow studies confirmed the diagnosis of AML with 50% blasts in the aspirate. She received induction chemotherapy using daunorubicin, cytarabine and thioguanine, after which she achieved complete remission. Post-remission chemotherapy given at the referring institution consisted of cytarabine, thioguanine, prednisone, cyclosphosphamide and etoposide. Allogeneic BMT was performed in our institution in October 1986 from her fully HLA-matched sister. Pre-transplant work-up, including chest X-ray, was normal. Conditioning chemotherapy consisted of CY/TBI, while GVHD prophylaxis consisted of the standard doses of MTX/CsA. Her immediate post-BMT course was unremarkable. However, she later developed chronic GVHD, mostly manifested by a wasting syndrome, which responded to steroid therapy. She remained healthy until June 1988, when she presented with fever, night sweats and a history of back pain. X-ray of the spine revealed destructive lesions involving the body of L1 and L2. CT scan of the spine showed evidence of a large paravertebral abscess. Fine-needle aspiration of the abscess was performed and 100 cm 3 of pus-like fluid was obtained and submitted for microbiologic studies and cultures. Retroperitoneal drainage of the abscess was carried out and the patient had an uneventful postoperative recovery, with improvement in her symptoms. The diagnosis of Mycobacterium tuberculosis was confirmed by acid-fast stain of the aspirated fluid and later by culture. The patient was started on rifampicin, ethambutol, and INH and anti-TB therapy was continued for 1 year. Follow-up X-ray of the spine showed a remarkable improvement in the previously noted destructive changes. At the time of the patient's last annual follow-up, she was doing well and her evaluation was unremarkable.
Case No. 2
A 34-year-old female underwent allogeneic BMT from her fully HLA-matched sister in September 1986, for the treatment of Philadelphia chromosome-positive CML in first chronic phase. Pre-transplant work-up, including chest Xray, was unremarkable. She received chemotherapy conditioning using BU/CY. She was enrolled in an ongoing study for GVHD prophylaxis using T cell depletion with CAMPATH antibody. Unfortunately, the patient failed to engraft and was rescued with her own cryopreserved chronic phase cells in November 1986. During the period of pancytopenia, she developed fever, cough, pulmonary infiltrate and was considered to have pulmonary tuberculosis based on positive sputum cultures for Mycobacterium tuberculosis. She was treated for 9 months using rifampicin, ethambutol and INH. After engraftment with her chronic phase cells, she was treated with hydroxyurea and did well until mid-1990. At this time she had clinical evidence of disease acceleration and karyotypic evolution, for which she underwent a second unmanipulated allogeneic BMT from the same donor in October 1990. She again received a conditioning regimen consisting of BU/CY and received the standard GVHD prophylaxis, consisting of MTX/CsA. The initial course of the second BMT was unremarkable, but unfortunately, she later developed severe veno-occlusive disease (VOD) of the liver and renal dysfunction. After this she developed bacterial and fungal sepsis with progressive multi-organ failure and expired. Autopsy specimens from the liver demonstrated fungal colonization both on histologic as well as microbiologic examination, but no evidence of TB infection.
Case No. 3
A 31-year-old male was discovered to have an elevated WBC count of 14.6 × 10 9 /l during a routine physical examination in late 1995. Physical examination was otherwise unremarkable. Bone marrow study confirmed the diagnosis of Philadelphia chromosome-positive CML in chronic phase. He was initially treated with hydroxyurea and later underwent allogeneic BMT from his fully HLA-matched sister in March 1996. Pre-transplant work-up, including chest X-ray, was unremarkable. Conditioning chemotherapy consisted of BU/CY and GVHD prophylaxis consisted of standard doses of MTX/CsA. He achieved an ANC Ͼ500/mm 3 at day 20. A few days later, he developed grade II acute GVHD of the skin and was treated with i.v. methylprednisolone. His post-transplantation course was complicated by CMV infection treated with ganciclovir and he developed secondary neutropenia requiring G-CSF administration. On day 60, he developed hemorrhagic cystitis which was resistant to all measures and finally required intravesical installation of formalin. Around day 120, he developed symptoms of cough and then shortness of breath. Chest X-ray showed patchy areas of consolidation in the right middle lobe and the left upper lobe which were consistent with pneumonia. CT scan of the chest showed extensive consolidation with air bronchogram in the right upper lobe, right middle lobe and left upper lobe with no evidence of cavitation. Broncho-alveolar lavage (BAL) stains were negative for bacteria, fungi, acid-fast bacilli, Pneumocystis carinii and CMV. Subsequently, he had an open-lung biopsy which showed necrotizing granulomatous infiltration with diffuse alveolar damage, but no acid-fast bacilli on smear. Shortly after the open lung biopsy procedure, his condition rapidly deteriorated and he died secondary to septic shock and multi-organ failure. All specimens obtained by BAL and lung biopsy subsequently grew Mycobacterium tuberculosis. 
Case No. 4
A 38-year-old male presented with symptoms of weakness, fatigue and easy bruising in 1996. Work-up confirmed the diagnosis of AML M5-FAB sub-type. He received induction chemotherapy using idarubicin, cytarabine and etoposide, followed by consolidation chemotherapy with highdose cytarabine, with no complications. He then underwent allogeneic BMT from his fully HLA-matched brother in March 1997. Pre-transplant work-up, including chest X-ray, was unremarkable. Conditioning therapy was with BU/CY. GVHD prophylaxis consisted of standard-dose MTX/CsA. During neutropenia, he developed fever with a negative work-up and was treated with broad-spectrum antibiotics.
He achieved an ANC Ͼ500/mm 3 at the end of the third week, and a few days later he developed grade II acute GVHD of the skin and liver and was treated with i.v. methylprednisolone. Shortly thereafter, he had evidence of CMV infection and was treated with ganciclovir. G-CSF was later added when he developed ganciclovir-induced neutropenia. Subsequently, the patient was discharged in a stable condition. On day 145, he presented with a history of grand-mal seizure twice associated with right-sided weakness. On admission, the WBC was 4.7 × 10 9 /l, hemoglobin 70 g/l and platelet count 16 × 10 9 /l. The creatinine was elevated at 211 mol/l and the serum sodium 127 mol/l. Chest X-ray was normal. CT scan of the brain showed mild dilatation of the ventricular system, with no other findings. Spinal tap was performed, with an opening pressure of 17 cm of water. Cerebrospinal fluid (CSF) showed a total cell count of 52 × 10 9 /l with 85% lymphocytes, glucose 2.0 mmol/l and protein 1298 mg/l. CSF gram stain, fungal stain and acid-fast stains were negative. The overall clinical picture was consistent with meningitis and the patient was empirically treated with ceftriaxone. His neurologic condition continued to deteriorate for the next 48 h. Repeat CT scan of the brain showed a large intraparenchymal abnormality in the left cerebral hemisphere, suggestive of a cerebral infarct with small hemorrhagic foci. His condition remained poor and he became more confused and disoriented, with a dense right-sided hemiplegia and a high-grade fever. He later became hypotensive and died. Colonies of Mycobacterium tuberculosis were isolated from the CSF 3 weeks post-mortem.
Discussion
Allogeneic BMT recipients are known to have severely impaired immunity, leading to increased risk of infection from bacterial, fungal and viral pathogens at different time intervals following BMT. Cell-mediated immunity is impaired as a result of the underlying illness, pre-transplantation conditioning chemotherapy, radiotherapy, and other co-morbid conditions. Most patients will not develop adequate immunocompetence for 1 year. Those who develop acute or chronic GVHD and who subsequently receive additional immunosuppressive therapy, as well as those who receive T cell-depleted grafts, tend to have protracted impairment of their immunocompetence, particularly T cell-mediated function.
1 A high incidence of mycobacterial infections is anticipated in these patients. This report represents our experience with Mycobacterium tuberculosis following allogeneic BMT (Table 1) , and concurs with the observations made by others [2] [3] [4] [5] [6] [7] (Table 2 ). Early diagnosis of Mycobacterium tuberculosis infection in BMT recipients can be difficult, because patients are severely immunosuppressed and often neutropenic. These factors can mask the febrile response to infection and possibly obscure typical tissue findings such as granulomatous reaction. Additionally, many of these patients have other ongoing infections that involve sites including the lungs. Also, the slow growth of Mycobacterium in culture causes further delay in establishing the diagnosis. New molecular techniques are now available that will hopefully aid early diagnosis of this infection. 8 Atypical presentation with involvement of extra-pulmonary sites (cases 1 and 4, herein) and as reported by others, 6, 7 can create an additional difficulty in establishing early diagnosis, particularly in allogeneic BMT patients with a history of GVHD receiving immunosuppressive therapy, as well as those who have received T cell-depleted grafts.
The prevalence of mycobacterial infection in the immunosuppressed BMT patient is lower than one would expect in this immunocompromised patient population, and this holds true in endemic and non-endemic areas. Prevalence of TB is also lower than TB rates in other organ transplant populations (Table 3) . 9 Renal transplant recipients in Saudi Arabia had a tuberculosis rate of 3.5%. 10 AIDS patients are another group of immunosuppressed patients in whom TB is more common. Incidence of tuberculosis in AIDS patients also varies according to location. Reports have ranged between 23% in Haiti and 54% in Africa. 11, 12 Seven out of 171 HIV/AIDS patients diagnosed in our institution had tuberculosis (rate of 4.1%). The 0.6% prevalence of TB in our allogeneic BMT series was about twice as high as that of other BMT patients from western Europe and USA (11 of 3803, or rate of 0.3%). 7 The annual incidence of TB cases in Saudi Arabia was 16 per 100 000 population in 1995. 13 In the United States, the rate was 7.4 per 100 000 population in 1997. 14 Purified protein derivative (PPD) skin tests tend to be positive in individuals living in endemic TB areas, either because of BCG vaccination in childhood (since it is routinely performed in some countries) or exposure to tuberculosis at an early age. Additionally, PPD skin test can turn negative in patients who are undergoing chemotherapy or receiving immunosuppressive therapy for BMT, and the PPD skin test is frequently negative even at the time of active infection. Routine prophylaxis against tuberculous infection for patients with skin test reactivity and a normal chest X-ray must be balanced against the possibility of hepatotoxicity in BMT patients, a population that is known to be at risk for developing liver dysfunction secondary to many other causes, including VOD, viral hepatitis, GVHD, medications and others. However, prophylaxis is recommended for patients previously exposed to tuberculosis, and should be considered in those with a positive PPD skin test in a non-endemic area.
